Ter Meer Steinmeister & Partner patent opposition analysis

The comprehensive analysis of Ter Meer Steinmeister & Partner opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Stay updated with the latest patent oppositions filed by Ter Meer Steinmeister & Partner

Patent NumberTitleApplicantOpposition DateOpposition Company
A Filler Compound And Use Of A Filler CompoundSAINT-GOBAIN PLACOAug 4, 2026AECHTER
Methods For Treating Atopic Dermatitis By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALS, INC.Jul 29, 2026LUIGI
Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or HyperglycemiaBOEHRINGER INGELHEIM INTERNATIONAL GMBHJul 24, 2026GENERICS UK
Methods For Treating Cancer With Anti-Pd-1 AntibodiesMERCK SHARP & DOHME LLCJul 22, 2026ABBOTT PRODUCTION OPERATIONS
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL-MYERS SQUIBB COMPANYJul 13, 2026MANZER
Ceramic Tile And Method For Manufacturing Ceramic TilesUNILIN, BVJun 10, 2026TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBB
Extended, High Dose Vegf Antagonist Regimens For Treatment Of Angiogenic Eye DisordersREGENERON PHARMACEUTICALS, INC.Jun 1, 2026INTAS PHARMACEUTICALS
Document, Method For Producing A Document, And A Device For Carrying Out The MethodLEONHARD KURZ STIFTUNG & CO. KGMay 21, 2026GIESECKEDEVRIENT CURRENCY TECHNOLOGY
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN (EUROPE) GMBHMay 20, 2026SANDOZ
Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECA ABMay 12, 2026SANDOZ